6 new development(s) in neoantigen vaccines today.
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world Connecting decision makers to a dynamic network of information, people and ideas, Bloo…
Adding the personalized mRNA-based cancer vaccine intismeran autogene to pembrolizumab significantly reduced the risk for recurrence or death by 42% in patients with high-risk melanoma who had undergone complete surgical resection. At 2 years, recurrence-free survival (RFS) was 8…
Updated results from the randomized phase II iNATURE trial, presented by FengMing P. Kong at ESMO 2026 , showed that combining a personalized neoantigen peptide vaccine with precision critical-lesion radiotherapy significantly improved progression-free survival in patients with h…
A personalized cancer vaccine administered alongside an immunotherapy drug reduced the risk of death or melanoma recurrence by 42%, according to results from a major clinical trial involving more than 1,000 patients. The phase three trial found that the combination of the vaccine…
TAPESTRY (https://tapestry.rokitalab.com) is a database and web application for exploring recurrent tumor-enriched splice junctions (TEJs) in pediatric brain tumors, cancers that carry few protein-coding mutations and therefore few mutation-derived neoantigens. However, TEJs repr…
Relevant work from earlier we're still surfacing — not today's news.